Device helps eliminate
human error in
medication dispensing
From the July 2015 issue of HealthCare Business News magazine
Device helps eliminate human error in medication dispensing
MedPass is specifically designed to eliminate the margin of human error in administration of pills in hospitals and long-term-care facilities. The MedPass system, with its individual locking pill-dispensers eliminates medication administering errors, so patients can rest assured that they receive the right pills, the right dosage, the right quantity, and from the right manufacturer. With 2,863 white capsules, 7,501 white round pills, 1,948 yellow round pills and 826 yellow capsules on the market, identifying proper medications and dosages is becoming increasingly difficult. This device has a greater than 99.9% error detection rate and was created to ensure hospitals and long-term care facilities are dispensing the right medication to patients every time.
Next-generation
jaundice meter
Next-generation jaundice meter
Ad Statistics
Times Displayed: 109945
Times Visited: 6642 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Dräger announced the release of its next-generation jaundice meter, the JM-105, a non-invasive bilirubinometer that provides fast, accurate, cost-effective and pain-free jaundice screenings for newborns. JM-105 can be used on children as young as 35-weeks’ gestational age. The rise of non-invasive transcutaneous bilirubin testing (TcB) changed the way hospitals identified at-risk infants. Dräger’s new JM-105 is one of the most advanced transcutaneous monitoring products available, measuring the yellowness of subcutaneous tissue in newborns as young as 35-weeks’ gestational age. Providing instantaneous screening of bilirubin results.
Home-use APD system
Baxter announced the completion of CE marking approval for an automated peritoneal dialysis (APD) system that integrates with the company’s web-based treatment monitoring platform, SHARESOURCE. By utilizing secure two-way connectivity, the HOMECHOICE CLARIA APD system allows providers to access timely and personalized data on patients’ home peritoneal dialysis (PD) therapies and make adjustments to the prescriptions as needed. It was designed for ease-of-use with a large, two-line display screen and a universal interface that can be programmed in 41 different languages.
